British company received permission to test covid vaccine in the form of a patch

As they say in a statement, the vaccine belongs to the second generation drugs. It is based on the use of T cells, which are able to recognize and destroy the cells of the human body affected by the virus.

It is noted that these cells begin to work immediately after infection. They prevent the multiplication of the virus in the human body and the development of the disease in humans. In addition, these cells prevent the virus from spreading to other people.

The vaccine developers claim that this principle of fighting the virus allows for longer lasting immunity and protection against coronavirus. Unlike vaccines, which trigger the production of antibodies in the human body, in this case, the vaccine begins to act immediately. In addition, as antibodies in the human body decrease, the effectiveness of the drug decreases.

The Emergex vaccine in the form of a patch will be convenient to use, the developers say. It can be stored at home at room temperature for up to three months. Storage conditions for the vaccine will make it easier to ship worldwide.

The drug will be tested in Switzerland. They will begin on January 3 next year. It is expected that 26 volunteers will be able to participate, half of whom will receive a higher dose of the vaccine, the rest - a weaker dose. Scientists expect to receive the first results of the tests as early as June next year.